Option Millionaires

[jimmybob]

lol ->BMO says Valeant could be near 'significant inflection point'
BMO Capital analyst Alex Arfaei says Valeant Pharmaceuticals could be on the verge of a "significant inflection point" after the company announced that its board committee has not identified any additional items that would require restatements beyond those required by matters previously disclosed. Valeant's financial misstatements so far do not support the fraud allegations, Arfaei tells investors in a research note, citing his firm's review. He believes the stock is undervalued relative to the company's underlying fundamentals. The analyst has a Market Perform on the shares, but his price target of $66 is well above the stock's current levels. Shares of Valeant are up $2.33, or 9%, to $28.44 in early trading